In estrogen receptor–positive breast cancer specifically, CDK4 has become a specific target; its activity is inhibited by palbociclib to suppress breast cancer growth both in vitro and in mouse models as well as among patients with breast cancer (31). This evidence concerns the gene ESR1 and breast carcinoma.